Target Information

Target General Infomation
Target ID
T63934
Former ID
TTDI01921
Target Name
Interferon alpha 2 ligand
Gene Name
IFNA2
Synonyms
IFNalpha2; Interferon alpha2; Interferon alphaA; LeIF A; IFNA2
Target Type
Successful
Disease Basal cell cancer [ICD9: 140-229, 173; ICD10: C44]
Bladder cancer [ICD9: 188; ICD10: C67]
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
HBV infection [ICD9: 070.2-070.3; ICD10: B16, B18.0, B18.1]
Hairy cell leukemia [ICD9: 202.4; ICD10: C91.4]
HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10: B17.1, B18.2]
Melanoma [ICD9: 172; ICD10: C43]
Mesothelioma [ICD9: 163; ICD10: C45]
Viral infections [ICD9: 054.0, 054.1, 054.2, 054.3, 075, 771.2, 052, 053; ICD10: B01, B02, A60, B00, B27, G05.1, P35.2]
Unspecified [ICD code not available]
Function
Produced by macrophages, IFN-alpha have antiviral activities.
BioChemical Class
Cytokine: interferon
UniProt ID
P01563
Sequence
MALTFALLVALLVLSCKSSCSVGCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFG
FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEA
CVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNL
QESLRSKE
Drugs and Mode of Action
Drug(s) Interferon Alfa-2b Drug Info Approved Melanoma [551871]
Peginterferon alfa-2a Drug Info Approved Hairy cell leukemia [536361]
Peginterferon alfa-2b Drug Info Approved HCV infection [536361], [542487]
Albinterferon alfa-2b Drug Info Phase 3 HCV infection [530007]
Hebergel Drug Info Phase 3 Viral infections [529448]
Interferon alpha 2a Drug Info Phase 3 HCV infection [525849]
P-1101 Drug Info Phase 3 HBV infection [524444]
Instiladrin Drug Info Phase 2 Bladder cancer [524056]
Interferon alpha-2b Drug Info Phase 2 HCV infection [550975]
Novaferon Drug Info Phase 2 Colorectal cancer [525215]
CIGB-128 Drug Info Phase 1 Basal cell cancer [549462]
SCH-721015 Drug Info Phase 1 Mesothelioma [523112]
Modulator Albinterferon alfa-2b Drug Info [530007]
CIGB-128 Drug Info
HAp-IFN Drug Info [550872]
Hebergel Drug Info [527899]
Instiladrin Drug Info [524056]
Interferon Alfa-2b Drug Info [556264]
Interferon alpha 2a Drug Info [533362]
Interferon alpha-2b Drug Info [550320]
Novaferon Drug Info [544388]
P-1101 Drug Info [530931]
Peginterferon alfa-2a Drug Info [556264]
Peginterferon alfa-2b Drug Info [556264]
SCH-721015 Drug Info [531615]
subalin Drug Info
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Regulation of autophagy
PI3K-Akt signaling pathway
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoxicity
Tuberculosis
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
Autoimmune thyroid disease
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Downstream signaling in na&amp
#xef
ve CD8+ T cells
Reactome Interferon alpha/beta signaling
Regulation of IFNA signaling
TRAF6 mediated IRF7 activation
Factors involved in megakaryocyte development and platelet production
WikiPathways Toll-like receptor signaling pathway
Type II interferon signaling (IFNG)
Interferon alpha/beta signaling
Regulation of toll-like receptor signaling pathway
References
Ref 523112ClinicalTrials.gov (NCT01162785) Phase IB Intravesical Administration of SCH 721015. U.S. National Institutes of Health.
Ref 524056ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
Ref 524444ClinicalTrials.gov (NCT01949805) Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera. U.S. National Institutes of Health.
Ref 525215ClinicalTrials.gov (NCT02455596) Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors.
Ref 525849Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000 Aug;18(16):2972-80.
Ref 529448Detection of PEGylated proteins in polyacrylamide gels by reverse staining with zinc and imidazole salts. Electrophoresis. 2008 Jun;29(11):2363-71.
Ref 530007Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 542487(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7462).
Ref 549462Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037683)
Ref 550975Clinical pipeline report, company report or official report of Hanall biopharma.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 524056ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
Ref 527899Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7. Epub 2005 Nov 28.
Ref 530007Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
Ref 530931Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8.
Ref 531615Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51.
Ref 533362Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60.
Ref 544388Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8.
Ref 550320Clinical pipeline report, company report or official report of Avarx.
Ref 550872CN patent application no. 1921880, Protein drug sustained-release microparticle preparation for injection and process for producing the same.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.